trial

L-arginine Study for Persistent Symptoms of Schizophrenia

NCTId NCT04054973
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Withdrawn
Enrollment 0 (actual)
Sponsored by University of Massachusetts, Worcester
Primary completion 2021-12-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2019-09-11
Primary completion
2021-12-31
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
L-ArginineSapropterin Dihydrochloride

Sponsors

University of Massachusetts, WorcesterLead Sponsor

Investigators

1
Xiaoduo Fan, MD, MPH, MSPrincipal Investigator

Sites

1 total
Worcester, United States

Linked catalysts

1
L-arginine Study for Persistent Symptoms of Schizophrenia — primary completion2021-12-31

Facts & assertions

4 sourced
Enrollment
0
Phase
PHASE2
Primary Completion Date
2021-12-31
Status
WITHDRAWN
relationships
The graph out of here
drug
L-Arginine
drug
Sapropterin Dihydrochloride
drug
lead_sponsor
University of Massachusetts, Worcester
company
indication
Schizo Affective Disorder
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Xiaoduo Fan, MD, MPH, MS
person